Pfizer Inc. halted a trial of an experimental gene therapy for muscular dystrophy after a child who received it died unexpectedly.
In an email, the company stated, “The patient, a little boy, had a cardiac arrest after receiving Pfizer’s one-time treatment last year”.
“The boy was part of a mid-stage study, now concluded, that enrolled children between the ages of 2 and 4”, the company continued.
The company went on to say, “Pfizer has paused administering the same gene therapy in a separate, final-stage study while it investigates the boy’s death”.
The study is looking into fordadistrogene movaparvovec, a gene therapy used to treat Duchenne muscular dystrophy, a rare and deadly muscle-wasting disease that primarily affects boys.
Pfizer stated, We are attempting to evaluate our investigational gene therapy while protecting the safety of the participants, which is our top priority”.
The final-stage trial included boys aged 4 and 8, and the goal was to see if the medication could reduce disease progression when compared to a placebo.
The study’s results are expected this year.
Sarepta Therapeutics Inc.’s competing gene therapy received fast approval in the United States last year.
Also read: Slovakia Records 1,100 Bomb Threats In A Day, Terror Investigation Launched
Gautam Adani, Chairman of the Adani Group, visited Puri in Odisha during the annual Rath…
Acharya Pramod Krishnam, stirred political debate by claiming an 'internal emergency' still exists within the…
Taking a crucial step toward positive transformation, social reform, and global peace, the Muslim Rashtriya…
India has been chosen to host the prestigious 2029 World Police and Fire Games in…
Gautam Adani, along with his wife and Karan, participated in the Rath Yatra in Puri,…
PM Narendra Modi interacted with Group Captain Shubhanshu Shukla, the first Indian to reach the…